Financing ·
On July 14, 2026, Cero Therapeutics Holdings, Inc. entered into a second amended and restated promissory note with SRX…
CEROCero Therapeutics Holdings, Inc.
On July 14, 2026, Cero Therapeutics Holdings, Inc. entered into a second amended and restated promissory note with SRX Global Inc. The agreement allows for a maximum aggregate borrowing of $2,085,200. To date, the company has drawn $750,000 from the original note, $663,600 on June 23, 2026, and $671,600 on July 14, 2026. The note carries a 10% annual interest rate, matures on May 28, 2027, and is convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over the preceding 20 days. Cero Therapeutics Holdings, Inc. is a biotechnology company.